TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04898322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-005
Description: 2.5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-005
Description: 5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
Study: NCT05323903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telesimulation
Description: Telesimulation is an application that is a teaching process by which telecommunication and healthcare simulation resources are used to provide education, training and assessment to learners at an off-site location. In this study, simulation was recorded and this was shared with the students through means of telecommunication.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telesimulation
Description: Telesimulation is an application that is a teaching process by which telecommunication and healthcare simulation resources are used to provide education, training and assessment to learners at an off-site location. In this study, simulation was recorded and this was shared with the students through means of telecommunication.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kahoot Game
Description: Kahoot is a game-based learning platform, used as educational technology in schools and other educational institutions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kahoot Game
Description: Kahoot is a game-based learning platform, used as educational technology in schools and other educational institutions.
Study: NCT05990764

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic, Prebiotic, Polyphenol-rich Extracts
Description: probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum) and elderberry and chokeberry extract~Once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic, Prebiotic
Description: probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum)~Once a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo~Once a day
Study: NCT04898322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-005
Description: 10mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04859595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Description: Monthly follow-up by telephone from M1 to M6. The interview will unroll in 2 stages, a first stage of discussion during which the speech therapist will take news of the patient. The second, more formal phase will be the opportunity to collect the data necessary for the validation of the primary and secondary outcomes. To do this, the speech therapist will use the Functional Oral Intake Scale (FOIS) score, the DHI and an interview grid.~The interview will be conducted using an interview sheet previously written by the project team. The following elements will be discussed: the description of oral food intakes (TIMES), the perceived swallowing handicap (DHI), the instructions related to the diet and their daily application, ongoing rehabilitation follow-ups, notable events as well, then his emotional and psychological experience in relation to the disorder.
Study: NCT04216823

Intervention type: DEVICE
Intervention: perfusion index
Description: perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients

Intervention type: DEVICE
Intervention: perfusion index
Description: perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients
Study: NCT05720546

Intervention type: OTHER
Intervention: Baseline Survey
Description: A survey that measures participant satisfaction will be offered to participants during infusion at baseline.

Intervention type: OTHER
Intervention: Baseline Survey
Description: A survey that measures participant satisfaction will be offered to participants during infusion at baseline.

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Semi-structured interviews will be conducted in the same infusion spaces.

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Semi-structured interviews will be conducted in the same infusion spaces.

Intervention type: OTHER
Intervention: Follow-up Survey
Description: A survey that measures participant satisfaction will be offered to participants during following infusion.

Intervention type: OTHER
Intervention: Follow-up Survey
Description: A survey that measures participant satisfaction will be offered to participants during following infusion.
Study: NCT04806919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesteron TID
Description: increasing the dose
Study: NCT04785638

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: INL-001 (bupivacaine hydrochloride) implant
Description: INL-001 (bupivacaine hydrochloride) implant
Study: NCT05751304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: (50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 5μg Dexametomidine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: (50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 0.1 mg/kg ketamine.
Study: NCT05611164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Software assisted selection of individual spermatozoa for intracytoplasmic sperm injection
Description: Half of the oocytes will be injected with a sperm selected with SiD's assistance
Study: NCT06254261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1225
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1225
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05912244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IO102/IO103
Description: IO102/IO103 will be administered subcutaneously on Days 1 and 15 of the first two 28-day cycles, and then on Day 1 only of subsequent cycles for two total years of treatment. Each vaccine contains 85ug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab-Relatlimab
Description: Nivolumab-relatlimab will be administered as a single infusion 160mg relatlimab and nivolumab 480 mg for all participants. Both agents will be combined in a single fixed-dose combination (FDC) as an intravenous 30-minute infusion every four weeks.
Study: NCT06459440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Task oriented Training
Description: Group Task-Oriented Training for individuals with Down syndrome is an approach that focuses on improving specific skills and promoting social interaction through collaborative activities. This training method involves organizing individuals with Down syndrome into small groups to work on tasks that target various developmental areas, such as motor skills, communication, and socialization. The tasks are designed to be meaningful, engaging, and relevant to the participants' daily lives.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Treatment
Description: 1.Week 1-2 : Foundation building (4 sessions per week) Gentle stretching exercises (20 minutes). Basic strengthening exercises (20 minutes) (26). Weeks 3-4: Balance and coordination (4 sessions per week ) Balance exercises and core stability (20 minutes). Coordination drills (20 minutes) (26). Weeks 5-6: Functional activities (4 sessions per week )~Incorporate functional activities into therapy (e.g., walking, reaching) (20 minutes)
Study: NCT06352346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compensatory brain game supporting Goal Management Training intervention
Description: o The investigational treatment is only given during the intervention phase (phase B), and consists of six treatment sessions. In the treatment sessions, patients learn and apply the GMT algorithm. This means that the multiple steps of the GMT as well as the actual performance of the IADL-task goals will be learned under guidance of a therapist. In order to facilitate generalization, patients will learn to use the algorithm during the performance of untrained tasks by playing the treatment supporting Plan Game. Because of this, patients are able to practice the application of the GMT algorithm independently outside the therapy session. Besides, the intervention also includes a Plan Tool. This is a mobile application that can be used as an aid during the performance of (instrumental) activities of daily living (IADL) tasks in order to perform activities more independently. The GMT treatment sessions are given twice a week (max. 60 minutes for each attendance).
Study: NCT06502639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: theraplay program
Description: A play therapy method called thermaplay aids in children's development of stronger bonds and relationships with others. It emphasizes the parts of communication that are nonverbal. When it comes to giving cerebral palsy children with hand therapy that is both effective and motivating, fun approaches have been shown to be both successful and appealing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: conventional physical therapy program for like stretching and strengthening exercises, sponge ball exercises to the hand, and hand weight bearing exercises
Study: NCT06138418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurotomy
Description: Surgical treatment of spastic foot
Study: NCT05697224

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: urinary micro RNA detection
Description: Urinary Sha-miR-71a gene expression analysis Total RNA extraction and purification Sha-miR_71a gene expression analysis MAPK-3 gene expression analysis

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: urinary micro RNA detection
Description: Urinary Sha-miR-71a gene expression analysis Total RNA extraction and purification Sha-miR_71a gene expression analysis MAPK-3 gene expression analysis
Study: NCT06481462

Intervention type: PROCEDURE
Intervention: Intrathecal Morphine (ITM)
Description: morphine 100 mcg + 12.5 mg bupivacaine + 10 mcg fentanyl

Intervention type: PROCEDURE
Intervention: Quadratus Lumborum II (QLB-II) Block
Description: 12.5 mg bupivacaine + 20 mcg fentanyl bilateral QLB block (posterior tip 2) 25 cc 0.25% bupivacaine
Study: NCT05993442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimised kangaroo care
Description: The intervention of optimised KC implementation consists of two components. Component 1 defines the targeted StSC for optimised KC, while component 2 is the implementation support to put in place a tailored implementation strategy.,
Study: NCT06293781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Web-based ACT
Description: ACT program delivered online

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual for major depressive disorder

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual for major depressive disorder
Study: NCT05845749

Intervention type: DRUG
Group type: OTHER
Intervention: Vosoritide Injection [Voxzogo]
Description: Vosoritide will be given via a once daily subcutaneous injection at a dose of 15 ug/kg/day, at approximately the same time each day when feasible. Vosoritide will be supplied to the subject as 0.4 mg vial, 0.56 mg vial or 1.2 mg vials to be reconstituted with sterile water up to 0.8 mg/mL or 2 mg/mL concentrations for injection. The volume to be administered (injection volume) will be based on the subject's body weight and the concentration of vosoritide. All supplies will be provided to the subject for home based administration after training at the study site.
Study: NCT04689828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: administered intravenously once every 6 weeks (1 cycle) for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 185 MBq (3 - 5 mCi).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-PSMA-11
Description: single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 185 MBq (3 - 5 mCi).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARDT
Description: administered orally on a continuous basis, as per package insert and guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Best supportive/best standard of care as defined by the local investigator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care
Description: Best supportive/best standard of care as defined by the local investigator
Study: NCT05009264

Intervention type: PROCEDURE
Intervention: OMT
Description: OMT will be performed on identified areas of trapezius trigger points
Study: NCT06639334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasttrack pathway for THA/HE prosthesis reduction
Description: The purpose of this study is to design a fast-track pathway for patients referred to the University Hospital of Southern Denmark, Esbjerg, with high probability of having a dislocated hip prosthesis with the primary aim to reduce the time from arrival to reduction and the total hospitalization time.~The intervention is changed logistic and work pathways at the hospital that should reduce time to reduction significantly. For detailed description we refer to the uploaded protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pathway for THA/HE prosthesis reduction
Description: Standard treatment for a dislocated THA/HA at our institution is education in general anesthesia at the operating theater. For detailed description we refer to the uploaded protocol.
Study: NCT05574062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study Phase: MiniMed 780G Auto Mode with G4S sensor
Description: Subjects will start using the MiniMed™ 780G system in Auto Mode with G4S sensor.
Study: NCT05574062

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Study Phase: MiniMed 780G Manual Mode with G4S sensor
Description: Subjects will start using the MiniMed™ 780G system in Manual Mode.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuation phase: MiniMed 780G BLE 2.0 with DS5 sensor
Description: Subjects will start using the MiniMed 780G BLE 2.0 with DS5 sensor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuation Phase MiniMed 780G Auto Mode with G4S sensor
Description: Subjects will start using the MiniMed™ 780G system in Auto Mode with G4S sensor.
Study: NCT06354257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE/LNG
Description: One dose of EE and LNG is administered on Day 1 of treatment period 1 and one dose of EE/LNG co-administered with GSK3036656 DL 2 is given on Day 15 of treatment period 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656 Dose Level 1
Description: A loading dose of GSK3036656 with DL 1 is administered on Day 4 of treatment period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656 Dose Level 2
Description: One dose of GSK3036656 DL 2 is administered once a day from Day 5 to Day 14 of treatment period 2. In treatment period 3 a single dose of GSK3036656 DL 2 co-administered with EE/LNG is given on Day 15, then GSK3036656 DL 2 once a day from Day 16 to Day 17.
Study: NCT06321809

Intervention type: BEHAVIORAL
Intervention: intensive lifestyle
Description: INTENSIVE LIFESTYLE INTERVENTIONS

Intervention type: BEHAVIORAL
Intervention: intensive lifestyle
Description: INTENSIVE LIFESTYLE INTERVENTIONS
Study: NCT03965702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of a decision support system on the EV1000 monitoring (AFM mode)
Description: The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical decision support system for fluid administration called AFM (assisted fluid management) Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual application of the GDFT protocol (standard of care)
Description: Manual application of a GDFT protocol to guide fluid administration. Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
Study: NCT05901519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Patients will be treated with PO prednisone, once a day, at a dose of 60 mg/day
Study: NCT06345534

Intervention type: DEVICE
Group type: OTHER
Intervention: Questionnaire
Description: Patients will be asked to complete questionnaires at different times (before, during and after radiation) to evaluate which schedule gives the fewest side effects and the best quality of life.~The basic questionnaire and questionnaire about early side effects will be completed weekly up to 6 weeks after radiotherapy. The questionnaire about late side effects will be completed: after 6 months, 1 year, 2 years, 3 years, 4 years and 5 years.

Intervention type: DEVICE
Group type: OTHER
Intervention: Questionnaire
Description: Patients will be asked to complete questionnaires at different times (before, during and after radiation) to evaluate which schedule gives the fewest side effects and the best quality of life.~The basic questionnaire and questionnaire about early side effects will be completed weekly up to 6 weeks after radiotherapy. The questionnaire about late side effects will be completed: after 6 months, 1 year, 2 years, 3 years, 4 years and 5 years.
Study: NCT05451017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition
Description: a single dose of 1 mg AEF0117 in fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition
Description: a single dose of 1 mg AEF0117 in fasting condition
Study: NCT05156450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone
Description: Treatment with TQB3616 in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer.
Study: NCT04557423

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community-Based Education
Description: A previously evaluated educational intervention delivered in community settings. Includes culturally- and linguistically-appropriate materials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-Based Education
Description: A previously evaluated educational intervention delivered in community settings. Includes culturally- and linguistically-appropriate materials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Navigation to Screening
Description: Community health educators provide navigation assistance to access clinic-based cervical cancer screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation to Screening
Description: Community health educators provide navigation assistance to access clinic-based cervical cancer screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV Self-Sampling
Description: An HPV self-sampling kit will be provided for home-based collection of cervical samples. Samples will be sent for analysis of HPV subtypes.
Study: NCT05852431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegozafermin
Description: Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT06417931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education and counselling
Description: The pharmacist intervention was aimed at identifying and addressing barriers to treatment adherence through tailored strategies
Study: NCT05814159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: sub cutaneous daily injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sub cutaneous daily injection
Study: NCT05057013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMBD-001
Description: Participants with advanced solid tumours will receive their assigned dose level of HMBD-001 diluted in 0.9% sodium chloride, administered once a week as a 120-minute intravenous (IV) infusion. Cycles are 28 days with no break in between; administration may continue for up to 6 cycles but may continue for longer if the participant is deemed to be benefitting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMBD-001 and enzalutamide
Description: Participants with metastatic castration resistant prostate cancer (mCRPC) confirmed as HER3 positive with no PTEN loss or with a NRG1 fusion rearrangement will receive the HMBD-001 recommended Phase 2 dose (RP2D) as determined in Part A, diluted in 0.9% sodium chloride and administered once a week as a 120-minute IV infusion, in combination with enzalutamide administered at a fixed dose of 160 mg once daily, in 28-day cycles with no break between cycles. Immediately before commencing combination therapy, participants may receive one 28-day cycle of enzalutamide monotherapy to confirm that their disease does not respond to enzalutamide alone. HMBD-001 may be administered for up to 6 cycles; enzalutamide may be continued until disease progression or unacceptable toxicity.
Study: NCT06455904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Training sessions
Description: The training program will be performed during 15 weeks, with one session per week.